Background: Obesity is characterized by low-grade chronic inflammation, elevated circulating cytokines, and hepatic overexpression of suppressor of cytokine signaling (SOCS) proteins, which are negative regulators of the JAK/STAT pathway activated by pro-inflammatory cytokines, including the tumor necrosis factor-alpha (TNF-alpha). SOCS3 is also implicated in hypertriglyceridemia associated to insulin-resistance (IR) (1). Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) levels are frequently found to be positively correlated to IR and plasma very low-density lipoprotein-triglycerides (VLDL-TG) concentrations (2). AIM: In a condition of IR, to investigate the role of SOCS3 on de novo lipogenesis, cholesterol biosynthesis and PCSK9 expression in human HepG2 cell line. Results: To resemble a condition of chronic-inflammation (characterized by SOCS3 activation), we stimulated HepG2 cells with TNF-alpha and resistin and then generated an HepG2 cell line overexpressing SOCS3 (HepG2SOCS3). TNF-alpha and resistin induced both SOCS3 and PCSK9 expression in HepG2 cells and for TNF-alpha. These effects were inhibited by transfection with siRNA anti-STAT3, suggesting the involvement of the JAK/STAT pathway. In parallel retroviral SOCS3 overexpression determined a complete abrogation of STAT3 phosphorylation. HepG2SOCS3 showed higher de novo lipogenesis (induction of fatty-acid synthase (FAS) mRNA by 3.59±0.40 fold; stearoyl-CoA desaturase (SCD-1) mRNA by 1.92±0.12 fold; and apolipoproteinB (apoB) secretion by 3.47±0.09 fold). These responses were associated with significant increase of SCD-1 protein, activation of SREBP-1, accumulation of cellular TG, and secretion of apoB. HepG2SOCS3 cells express higher levels of PCSK9 mRNA (3.48±0.35 fold) and protein secretion (2.18±1.13 fold). No relevant changes of HMG-CoA reductase, low-density lipoprotein receptor levels and cholesterol biosynthesis were found. In addition, TNF-alpha significantly induced SCD-1, apoB and FAS mRNA levels (2.11±0.43, 1.60±0.33 and 1.39±0.21 fold, respectively). Insulin stimulation further induced FAS, SREBP-1 and PCSK9 mRNA levels to a similar extent in control and SOCS3-overexpressing cells, although the overall mRNA levels of these genes were significantly higher in HepG2SOCS3 cells. Akt and IRS-1 phosphorylation in response to insulin was attenuated in HepG2SOCS3, supporting IRS-1 inhibition as the mechanism of abrogated Akt, and STAT3 phosphorylation. Conclusions: Our data provide evidence for the JAK/STAT dependent expression of PCSK9 in hepatic cell line, suggesting the potential molecular basis of the direct relationship between PCSK9, triglycerides levels and IR observed in clinical settings.
SOCS-3 induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line: a potential link between hypertriglyceridemia and insulin resistance / M. Ruscica, C. Ricci, C. Macchi, J. Liu, P. Magni, A. Corsini, N. Ferri. ((Intervento presentato al 98. convegno Annual Meeting of the Endocrine Society tenutosi a Boston nel 2016.
SOCS-3 induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line: a potential link between hypertriglyceridemia and insulin resistance
M. RuscicaPrimo
;C. RicciSecondo
;C. Macchi;P. Magni;A. CorsiniPenultimo
;
2016
Abstract
Background: Obesity is characterized by low-grade chronic inflammation, elevated circulating cytokines, and hepatic overexpression of suppressor of cytokine signaling (SOCS) proteins, which are negative regulators of the JAK/STAT pathway activated by pro-inflammatory cytokines, including the tumor necrosis factor-alpha (TNF-alpha). SOCS3 is also implicated in hypertriglyceridemia associated to insulin-resistance (IR) (1). Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) levels are frequently found to be positively correlated to IR and plasma very low-density lipoprotein-triglycerides (VLDL-TG) concentrations (2). AIM: In a condition of IR, to investigate the role of SOCS3 on de novo lipogenesis, cholesterol biosynthesis and PCSK9 expression in human HepG2 cell line. Results: To resemble a condition of chronic-inflammation (characterized by SOCS3 activation), we stimulated HepG2 cells with TNF-alpha and resistin and then generated an HepG2 cell line overexpressing SOCS3 (HepG2SOCS3). TNF-alpha and resistin induced both SOCS3 and PCSK9 expression in HepG2 cells and for TNF-alpha. These effects were inhibited by transfection with siRNA anti-STAT3, suggesting the involvement of the JAK/STAT pathway. In parallel retroviral SOCS3 overexpression determined a complete abrogation of STAT3 phosphorylation. HepG2SOCS3 showed higher de novo lipogenesis (induction of fatty-acid synthase (FAS) mRNA by 3.59±0.40 fold; stearoyl-CoA desaturase (SCD-1) mRNA by 1.92±0.12 fold; and apolipoproteinB (apoB) secretion by 3.47±0.09 fold). These responses were associated with significant increase of SCD-1 protein, activation of SREBP-1, accumulation of cellular TG, and secretion of apoB. HepG2SOCS3 cells express higher levels of PCSK9 mRNA (3.48±0.35 fold) and protein secretion (2.18±1.13 fold). No relevant changes of HMG-CoA reductase, low-density lipoprotein receptor levels and cholesterol biosynthesis were found. In addition, TNF-alpha significantly induced SCD-1, apoB and FAS mRNA levels (2.11±0.43, 1.60±0.33 and 1.39±0.21 fold, respectively). Insulin stimulation further induced FAS, SREBP-1 and PCSK9 mRNA levels to a similar extent in control and SOCS3-overexpressing cells, although the overall mRNA levels of these genes were significantly higher in HepG2SOCS3 cells. Akt and IRS-1 phosphorylation in response to insulin was attenuated in HepG2SOCS3, supporting IRS-1 inhibition as the mechanism of abrogated Akt, and STAT3 phosphorylation. Conclusions: Our data provide evidence for the JAK/STAT dependent expression of PCSK9 in hepatic cell line, suggesting the potential molecular basis of the direct relationship between PCSK9, triglycerides levels and IR observed in clinical settings.File | Dimensione | Formato | |
---|---|---|---|
Abstract Endocrine Society 2016 NF-Uploaded.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
292.59 kB
Formato
Adobe PDF
|
292.59 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.